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Abstract
Aconitum laciniatum is used in Bhutanese traditional medicine for treating various chronic infections and
inflammatory conditions. We carried out in-depth isolation and characterization of the phytochemicals from
the root component and determined the anti-inflammatory effects of the isolated compounds against
chemically-induced colitis in mice. Five diterpenoid alkaloids - pseudaconitine, 14-veratroylpseudaconine,
14-O-acetylneoline, neoline, and senbusine A - were isolated from A. laciniatum for the first time. Two of the
alkaloids were tested for anti-inflammatory properties in the TNBS-induced colitis model in mice. Various
parameters were measured to assess pathology including weight loss, clinical and macroscopic scores,
histological structure and IFN-γ production in the gut. Of the two alkaloids tested, 14-O-acetylneoline
showed significant protection against different parameters of colitic inflammation. Compared to control mice
that received TNBS alone, mice treated with 14-O-acetylneoline experienced significantly less weight loss and
had significantly lower clinical scores, macroscopic pathology and grades of histological inflammation.
Moreover, colonic IFN-γ mRNA levels were significantly reduced in mice that received 14-O-acetylneoline
compared to control mice that received TNBS alone. This alkaloid is now considered a novel anti-colitis drug
lead compound.
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Diterpenoid alkaloids of Aconitum 
laciniatum and mitigation 
of inflammation by 14-O-
acetylneoline in a murine model of 
ulcerative colitis
Phurpa Wangchuk1,2, Severine Navarro1, Catherine Shepherd1, Paul A. Keller2, 
Stephen G. Pyne2 & Alex Loukas1
Aconitum laciniatum is used in Bhutanese traditional medicine for treating various chronic 
infections and inflammatory conditions. We carried out in-depth isolation and characterization of 
the phytochemicals from the root component and determined the anti-inflammatory effects of the 
isolated compounds against chemically-induced colitis in mice. Five diterpenoid alkaloids -  
pseudaconitine, 14-veratroylpseudaconine, 14-O-acetylneoline, neoline, and senbusine A - were 
isolated from A. laciniatum for the first time. Two of the alkaloids were tested for anti-inflammatory 
properties in the TNBS-induced colitis model in mice. Various parameters were measured to assess 
pathology including weight loss, clinical and macroscopic scores, histological structure and IFN-γ 
production in the gut. Of the two alkaloids tested, 14-O-acetylneoline showed significant protection 
against different parameters of colitic inflammation. Compared to control mice that received TNBS 
alone, mice treated with 14-O-acetylneoline experienced significantly less weight loss and had 
significantly lower clinical scores, macroscopic pathology and grades of histological inflammation. 
Moreover, colonic IFN-γ mRNA levels were significantly reduced in mice that received 14-O-
acetylneoline compared to control mice that received TNBS alone. This alkaloid is now considered a 
novel anti-colitis drug lead compound.
Aconitum laciniatum (Ranunculaceae) is one of the 100 species of aconites reported from the temperate 
and alpine regions of the northern hemisphere, including Bhutan1. Traditionally, aconites have been 
used in Asia, Alaska, and Europe for a wide range of applications ranging from warfare, hunting, covert 
human poisons and in traditional medicines2. In European homeopathy and Asian traditional medicines, 
many species of aconites are used for treating various ailments, particularly those with an inflammatory 
basis3. In Bhutanese traditional medicine (BTM), of the 19 Aconitum species reported4, three of them 
including A. laciniatum, A. violaceum and A. orochryseum are used in the preparation of 25 polyherbal 
formulations for treating numerous disorders including inflammatory conditions1,5. Many Aconitum spe-
cies are poisonous due to their rich content of diterpenoid alkaloids and need to be pre-processed and 
detoxified prior to their use6–8. However, carefully defined doses have been demonstrated to contrib-
ute to the desired clinical effects8–10. In modern biomedicine, aconite-containing ointments, including 
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AconitysatTM, BrinpaxTM, EtermolTM and PectovoxTM, are used as anodynes in the treatment of chronic 
rheumatism, neuralgia and sciatica11,12.
Phytochemically, more than 197 diterpenoid alkaloids (DA) with complicated structures have been 
isolated from 56 Aconitum species of pharmacological significance13–15. These Aconitum DA have been 
reported to possess a broad range of bioactivities including anti-inflammatory properties3,9,16–21.
All inflammatory conditions, especially the inflammatory bowel diseases (IBD), are chronic 
immune-mediated diseases with multi-factorial aetiologies influenced by genetics, environment, diet 
and the composition of the gut microbiota22. The prevalence of IBD is rising dramatically in developed 
countries, and populations previously considered to be low risk (such as in Japan and India) are now 
experiencing an increase in the incidence of IBD23. Current treatment for IBD includes corticosteroids 
and biologics such as monoclonal antibodies targeting Tumour Necrosis Factor (TNF), but these drugs 
manage the disease rather than cure it, and drug failure rates are high24, precipitating the need for new 
approaches to treat IBD. A recent review on herbal and plant therapies for the treatment of human IBD25 
noted that 27 clinical studies have been conducted by administering 11 herbal/plant therapies to a total 
of 1,874 IBD patients. Of the 11 plant samples, seven of them were reported to have beneficial effects on 
ulcerative colitis, while four plants resulted in clinical remission of Crohn’s disease.
In this study, we explored one of the Bhutanese medicinal plants, A. laciniatum, which is traditionally 
used for treating chronic parasitic and microbial infections, as well as inflammatory conditions26. Its 
flowers, leaves and roots are collected annually for formulating at least five important polyherbal BTM 
formulations5. Our earlier work on the crude methanol extract of this plant showed partial inhibition 
of the production of the pro-inflammatory cytokine, TNF-α by LPS-activated monocytes27. Directed by 
this finding and its ethnopharmacological uses, we carried out in-depth isolation and characterization 
of the phytochemicals and determined the anti-inflammatory effects of the isolated compounds against 
chemically-induced colitis in mice.
Results
In the current study, we isolated, for the first time from A. laciniatum, five diterpenoid alkaloids and 
showed that one of the compounds protected mice against inflammation in the trinitrobenzoylsulfonic 
acid (TNBS)-induced mouse model of colitis that shares many key features with human ulcerative colitis.
Phytochemical isolation and characterization. About 165 g of crude MeOH extract was obtained 
from two kilograms of dry powdered roots of A. laciniatum upon extraction with MeOH giving an 
extractive value of 8.25% (w/w). Through an acid-base alkaloid isolation method, the DCM-1 and DCM-2 
extracts were obtained. We repeatedly subjected these extracts to the silica gel column and preparatory 
thin layer chromatography separation protocols to obtain five C19-diterpenoid alkaloids (Fig. 1). Initial 
purification of DCM-1 fraction yielded compounds 1 and 2 (Fig. 1). Compound 1 (1.9 g) was identified 
as the major chemical constituents of the plant. Its LR-ESI-MS showed a [M + H+] peak at (m/z): 690 
Figure 1. C19-diterpenoid alkaloids isolated from A. laciniatum (1-5). pseudaconitine (1), 
14-veratroylpseudaconine (2), 14-O-acetylneoline (3), neoline (4), senbusine A (5).
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and the LR-EI-MS ion fragmentation pattern and the 1H-NMR spectroscopic data of this alkaloid (1) 
agreed well with those of pseudaconitine reported in the literature28. Cross-examination of the published 
literature found that this compound was isolated earlier from the roots of other aconites29. Compound 
2 was isolated as an amorphous creamy white solid and its LR-ESI-MS displayed the [M + H+] peak at 
(m/z): 648 corresponding to the molecular formula of C34H49NO11 (M + H+, calculated for 648.3384). Its 
1H-NMR spectroscopic data agreed with those of 14-veratroylpseudaconine reported from A. ferox30 and 
A. falconeri29. From another fraction DCM-2, compounds 3, 4 and 5 were obtained (Fig. 1). Compound 
3 was isolated as an amorphous creamy white solid. Its LR-ESI-MS showed a [M + H+] peak at (m/z): 
480 and the HR-EI-MS showed a peak at 480.2955 corresponding to the protonated molecular formula 
C26H41NO7. The 1H-NMR and 13C-NMR spectroscopic data agreed with those of 14-O-acetylneoline 
isolated from the aphids Brachycaudus aconite, which lives and feeds on A. napellus31. Compound 4 
was isolated as an amorphous powder and its LR-ESI-MS showed a [M + H+] peak at (m/z): 438 and 
the HR-EI-MS exhibited a peak at 438.2863 which corresponded to the protonated molecular formula 
of C24H39NO6. These 1H-NMR spectroscopic data agreed with those of neoline that was isolated previ-
ously from A. ferox28. Compound 5 was isolated as an amorphous powder and its LR-ESI-MS showed a 
[M + H+] peak at (m/z): 424. The 1H-NMR as well as its APT spectroscopic data agreed with those of 
senbusine A isolated from A. carmichaeli and A. ferox28,32. To the best of our knowledge, compounds 2 
and 3 have never been tested for any biological activities.
Preliminary assessment of 14-veratroylpseudaconine and 14-O-acetylneoline for their 
anti-inflammatory activities in the TNBS-induced colitis mouse model. We carried out 
preliminary screening of compounds 2 and 3 (14-veratroylpseudaconine and 14-O-acetylneoline) 
using the TNBS-induced colitis model in mice33–35, monitoring just weight loss initially (data not 
shown). 14-Veratroylpseudaconine exacerbated the colitic inflammation induced by TNBS, however 
14-O-acetylneoline induced significant protection against TNBS-induced weight loss. Further stud-
ies in the colitis model were therefore restricted to just 14-O-acetylneoline. Upon administration of 
14-O-acetylneoline at doses of 10, 20, and 50 μ g per mouse, mice were monitored and scored daily for 
mortality and clinical signs including changes in weight loss, mobility, piloerection and faecal consist-
ency. At the end of the trial macroscopic pathology, histological structure and IFN-γ production in the 
gut of the mice were evaluated.
Treatment with 14-O-acetylneoline protected mice from weight loss and improved clini-
cal outcome. Upon TNBS administration, all mice lost weight within the first 24 hours. However, 
mice treated with different doses (10, 20, and 50 μ g) of 14-O-acetylneoline began to gain weight in 
a dose dependent manner from day 2 (Fig.  2a). Among the three doses studied, the 20 μ g dose of 
14-O-acetylneoline showed the best protective effects in terms of overall clinical scores (P = 0.0001) on 
day 3 compared to the TNBS-only group (Fig. 2b). All three doses of 14-O-acetylneoline conferred highly 
significant protection against pilorerection (Fig. 2c) and mobility (Fig. 2d) compared to the TNBS-only 
group. When faecal consistency was measured, the 20 and 50 μ g doses of 14-O-acetylneoline resulted in 
significantly improved faecal consistency compared to the TNBS-only group (Fig. 2e).
Reduced pathological changes after administration of 14-O-acetylneoline. On day 3, mice 
were euthanized and the colons were removed and assessed for changes in macroscopic appearances 
including adhesion, bowel wall thickening, mucosal oedema, ulceration, necrosis, and colon length. Mice 
treated with the 20 μ g dose of 14-O-acetylneoline had significantly reduced pathology scores (Fig.  3a) 
(P = 0.0476) and longer colon lengths (Fig. 3b) (P = 0.0160) compared to TNBS-only mice. We observed 
a trend towards reduced macroscopic pathology in colon tissues of mice treated with the 50 μ g dose of 
14-O-acetylneoline compared to TNBS-only controls, but the change did not reach significance. Colon 
lengths of mice treated with 50 μ g 14-O-acetylneoline were however significantly longer than those of 
TNBS-only mice (P = 0.0023).
Inhibition of colonic IFN-γ production by 14-O-acetylneoline. The clinical and macroscopic 
pathology scores were consistent with reduced production of IFN-γ in the colon tissues of mice that 
received 14-O-acetylneoline in a dose dependent manner. While all doses resulted in reduced IFN-γ 
production, mice that received 10 μ g (P = 0.0271) and 20 μ g (P = 0.0242) doses exhibited significantly 
lower IFN-γ levels than TNBS-only mice group (Fig. 3c). The naive group, as expected, showed the low-
est IFN-γ levels (P = 0.0011). Mice that received the 50 μ g dose also showed lower levels of IFN-γ than 
TNBS-only mice, although the reduction was not significant.
Histological analysis reveals protection of colon from TNBS-induced inflammation. The 
H/E stained paraffin-embedded colon sections were observed for histological changes induced by TNBS 
administration. Colons from the untreated naive group showed normal tissue architecture with a healthy 
number of goblet cells (Fig.  4-Naive). The colons of TNBS-only mice had severe lesions and extensive 
damage to the gastric mucosa as shown by the histological photomicrographs (Fig. 4-TNBS). This group 
showed mucosal congestion and erosion, inflammatory cell infiltrate, and high levels of leukocyte and 
polymorphonuclear cell infiltration in the lamina propria, intraepithelial compartments, and colon wall 
www.nature.com/scientificreports/
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with evidence of oedema, destruction and loss of healthy goblet cells; and thickening of the lamina pro-
pria and colon wall. None of the tissues treated with different doses of 14-O-acetylneoline showed the 
characteristic histological inflammation of the TNBS-only group. All doses reduced the area of ulceration 
and the level of leukocyte and polymorphonuclear cell infiltration. The general appearance of the histo-
logical architecture including lamina propria, epithelial compartments, goblet cell content, and colonic 
wall/musculature were unaffected and could not be distinguished from the naive group.
Discussion
Aconites are poisonous plants that require care and caution. It is noteworthy that, prior to their use in 
traditional medicines including BTM, aconite components are detoxified using region-specific tradi-
tional approaches, all of which are highly effective at reducing the toxicity of the plant by converting its 
diester diterpene alkaloids to their less toxic monoester diterpene forms10. Several publications8–10 have 
suggested that carefully defined amounts of toxic aconite diterpenoid alkaloids contribute to a diverse 
range of desired clinical effects, and it is essential to define the dose range that distinguishes toxicity 
from therapeutic efficacy. For example, atisinium chloride isolated from the Bhutanese medicinal plant, 
A. orochryseum, showed potent antimalarial activity against multi-drug resistant Plasmodium falciparum 
strains, K1CB1 and TM4/8.220, and 1-O-benzoylnapelline, a derivative of napelline isolated from the 
Aconitum species, showed antiarrhythmic activity that markedly exceeded that of the reference Class I 
antiarrhythmic drugs, novocainamide, quinidine and lidocaine17. A. laciniatum is traditionally indicated 
in BTM for treating disorders whose symptoms bare relevance to inflammatory conditions. Interestingly, 
our earlier study on the crude MeOH extract of A. laciniatum27 demonstrated its anti-inflammatory 
potential, and our work described herein suggests that 14-O-acetylneoline is responsible for at least some 
of this anti-inflammatory bioactivity.
Figure 2. Protective effects of 14-O-acetylneoline against weight loss and clinical symptoms induced 
by TNBS colitis. (a) The 20 μ g dose of 14-O-acetylneoline yielded highly significant (****P < 0.0001, 2-way 
ANOVA) protection against weight loss over the three-day duration of the experiment. (b) All three doses 
of 14-O-acetylneoline resulted in significantly reduced clinical scores in a dose-dependent manner over 
the three days of the experiment (*P = 0.0303 for 10 μ g dose, *P = 0.0017 for 20 μ g dose, **P = 0.0037 
for 50 μ g dose). (c) All three doses of 14-O-acetylneoline resulted in significantly reduced TNBS-induced 
piloerection in mice (0-2 scoring matrix) (****P < 0.0001). (d) All three doses of 14-O-acetylneoline resulted 
in significant protection against TNBS-induced reductions in mobility (0-3 scoring matrix) (****P < 0.0001). 
(e) The 20 and 50 μ g doses of 14-O-acetylneoline resulted in significantly improved faecal consistency after 
TNBS administration. Faecal scores (0-2 scoring matrix) (**P = 0.0011 for the 20 μ g dose and P = 0.0061 
for the 50 μ g dose). Statistical analyses were performed by pooling data from groups of mice from two 
independent but reproducible experiments.
www.nature.com/scientificreports/
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Ulcerative colitis is a chronic immune mediated disease with multi-factorial aetiology influenced by 
genetics, environment and the composition of the gut microbiota22,35. Its prevalence is rising in developed 
countries, with North America and Europe experiencing the steepest increases in incidence over the past 
few decades. Moreover, populations previously considered to be low risk (such as in Japan and India) are 
now experiencing an increase in the incidence of IBD, especially ulcerative colitis23. Current treatment 
for IBD includes 5-aminosalicylic acid, corticosteroids and biologics, each of which has drawbacks and 
limitations in efficacy36. Traditional medicinal and dietary plants are known to have anti-inflammatory 
properties, especially the dietary plants due to their relative non-toxicity. Despite their increasing use 
by IBD patients, a lack of understanding of the bioactive chemical components and mechanisms of 
anti-inflammatory action is an obstacle to the incorporation of many herbal or dietary treatments into 
mainstream medicine. A small number of studies have confirmed that medicinal and dietary plant 
extracts containing terpenoids, alkaloids, flavonoids and anthocyanins exert their anti-inflammatory 
activities by controlling the levels of various inflammatory cytokines37,38. For example, anthocyanin-rich 
fractions of blueberry and raspberries attenuate inflammation in TNBS-induced colitis by suppressing 
inflammatory cytokine production in macrophages39,40. Curcumin obtained from Curcuma longa showed 
potent anti-inflammatory activity in TNBS-induced colitis as well as in patients with uncreative colitis 
without side effects or toxicity25,41.
The gastrointestinal tract contains a mucus layer that serves as the front line of innate host defence, 
and its breakdown can result in colitis42. Our histological findings demonstrate that the administration 
of 14-O-acetylneoline prevented intestinal goblet cells from degenerating as a result of TNBS-induced 
Figure 3. Administration of 14-O-acetylneoline protects mice against TNBS-induced pathological 
changes, colon shortening and colonic IFN-γ production. (a) Dose 20 μ g of this compound reduced 
macroscopic scores over the three days of the experiment as compared to TNBS (*P < 0.0476). (b) Doses 20 
(*P = 0.0160) and 50 μ g (**P = 0.0023) of the same compound also reduced colon shortening as compared 
to TNBS. (c) Doses 10 and 20 significantly reduced IFN-γ production in mice as compared to TNBS 
(*P = 0.0242 for 20 μ g dose, *P = 0.0271 for 10 μ g dose, **P = 0.0011 for Naive). IFN-γ was measured using 
sandwiched ELISA. Statistical analyses were performed by pooling data from groups of mice from two 
independent but reproducible experiments.
www.nature.com/scientificreports/
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biochemical processes. Dysregulation of this intestinal goblet cell barrier allows the initiation of chronic 
inflammation that regulates the production of various mediators or proinflammatory cytokines includ-
ing TNF-α and IFN-γ 43–45. Both cytokines are the known intestinal signatures of IBD46,47. In our ear-
lier findings, the MeOH extract of A. laciniatum partially reduced the levels of TNF-α production in 
LPS-activated THP-1 monocytic cells27. Our findings herein using an animal model of colitis have shown 
that 14-O-acetylneoline isolated from A. laciniatum MeOH extract significantly reduced the production 
of IFN-γ by mouse colonic tissues in vivo. Although, TNF-α was not assessed in this study, it is likely 
that 14-O-acetylneoline is the active compound within the crude MeOH extract that inhibits production 
of this cytokine, although further testing is required.
In conclusion, we isolated five diterpenoid alkaloids from A. laciniatum and show that pseudaconitine 
is the major constituent of the plant. Of the two alkaloids tested in TNBS-induced colitis in mice, one 
minor compound, 14-O-acetylneoline showed significant anti-colitis activity. This finding corroborates 
the traditional claim of anti-inflammatory properties of this plant in BTM, however the mechanism by 
which 14-O-acetylneoline exerts its anti-colitic action cannot be elucidated from our current data. Future 
work will focus on isolation of larger quantities of this compound from A. laciniatum to facilitate investi-
gation into its mechanism of action and detailed pre-clinical studies including toxicity and derivatization 
analyses to generate synthetic 14-O-acetylneoline.
Materials and Methods
Plant material and isolation of compounds. A. laciniatum is locally known as “bdud-rtsi-lo-ma” 
or “tsan-dug”. This plant is an erect biennial herb, of 0.6–1.5 m in height, with less deeply dissected leaves 
(up to 15 cm in diameter), bluish flowers widely spaced in racemes, paired conical tubers and it grows on 
the grassy alpine mountain slopes of Bhutan at altitudes of 3500-4570 metres above sea level4. For this 
study, only the root of the plant was collected in August 2009 from Lingshi Makhang (Altitude: 4183 m; 
Latitude: 27° 50′ 29.9″ ; Longitude: 89° 25′ 41.5″ ; global positioning system point number (GPSPN): 
138; Site number: P138; Slope: 25°; Aspect: North-East). The herbarium voucher specimen number 93 
was assigned to it and the tissue was maintained at Menjong Sorig Pharmaceuticals, Thimphu, Bhutan. 
The dried roots of A. laciniatum were powdered and extracted with analytical/HPLC grade methanol 
(5 × 3 L over 48 h). The extract was filtered and then concentrated using a rotary evaporator at 35–50 °C 
to generate the crude MeOH extract (165 g). This extract was dissolved in MeOH/water (1:9) and then 
acidified with 5% HCl and fractionated with CH2Cl2 to obtain the acidic fraction (coded as DCM-1, 
(6.2 g)). The aqueous part was basified with NH4OH to pH 9–12 and then fractionated with CH2Cl2 to 
Figure 4. Administration of 14-O-acetylneoline protects mice against TNBS-induced colonic 
inflammation. Histological photomicrographs of hematoxylin and eosin-stained (H/E) paraffin sections 
(x200) of distal colon tissues, which were obtained from the representative groups of healthy mice (Naive) 
and mice that received TNBS and different doses of 14-O-acetylneoline. (a) Healthy goblet cells in Naive 
group, which can be also observed well preserved in the colon tissues of mice, treated with different doses 
of the compound. Destroyed goblets cells (b), erosion and thickening of lamina propria (c), and colon wall 
thickening (d) were observed in TNBS group.
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obtain the basic extract (coded as DCM-2, (2.4 g)) followed by ethyl acetate and n-butanol to obtain the 
respective EtOAc (0.11 g) and BuOH extracts (1.7 g). Each fraction was purified repeatedly using flash 
column chromatography packed with Merck Kieselgel 60 PF254. Aluminium-backed silica plates (0.2 mm 
silica thickness, Merck, normal and reverse phase) were used for separating isolates of smaller quantities. 
UV light (short wavelength of 254 nm, long wavelength of 366 nm) was used for visualization of the 
separated bands on TLC. Dragendorff ’s reagent was prepared48 for staining the TLC plate loaded with 
alkaloid fractions and pure compounds. Micromass Waters Platform LCZ (single quadrupole, MeOH as 
solvent) was used for obtaining the LR-ESI-MS. Shimadzu GCMS-QP-5050 was used for recording the 
LR-EI-MS by the direct insertion technique (at 70 eV). A Micromass Waters Q-ToF Ultima (quadrupole 
time-of-flight) mass spectrometer was used for acquiring HR-ESI-MS. A 500 MHz Varian Unity Inova, 
500 MHz Varian Premium Shield (VNMRS PS 54), and 300 MHz Varian Mercury spectrometer were 
used for obtaining NMR spectra (1H-NMR, gCOSY, 13C-NMR, APT, gHMBC, gHSQC, and gNOESY) 
using deuterated solvents (CD3OD or CDCl3) depending upon the solubility of compounds. The initial 
purification of the DCM-1 extract using silica gel packed CC and a gradient eluent solvent system of 
CH2Cl2/MeOH (100 mL, v/v ratio as 0:100, 10:90, 20:80, 30:70, 50:50) yielded eight fractions, DCM-1-F1 
to DCM-1-F8. Further separation of fraction DCM-1-F4 using PTLC plates with the solvent system of 
MeOH-CH2Cl2-NH4OH (2:23:6 drops) furnished a white solid, which upon crystallization with CHCl3/
MeOH (1:1) gave prisms. This was the major compound of the plant and was identified as pseudaconitine 
(1). Separation of fraction DCM-1-F8 using the PTLC plates with the solvent system of MeOH-CH2Cl2-
NH4OH (1:9:6 drops) yielded 14-veratroylpseudaconine (2). Another fraction DCM-2 was subjected to a 
silica gel packed CC and a gradient eluent solvent system of CH2Cl2/MeOH (100 mL, v/v ratio as 0:100, 
1:99, 2:98, 4:96, 8:92, 15:85, 30:70) yielded eight fractions, DCM-2-F1 - DCM-2-F8. Fraction DCM-2-F2 
when dried furnished amorphous white solid, which was identified as 14-O-acetylneoline (3). Fraction 
DCM-2-F3 upon drying under reduced pressure yielded neoline (4). Fraction DCM-2-F7 (105.0 mg) 
was further separated using PTLC plates with the solvent system of MeOH-CH2Cl2 (2:23), and which 
identified senbusine A (5).
Animal ethics and experimental TNBS-induced colitis. All animal procedures were conducted in 
accordance with the approved guidelines of The James Cook University Animal Ethics Committee. Male 
C57BL/6 mice (6 weeks old) were purchased from the Animal Resources Centre (Perth, Australia) and 
were housed and maintained in the QTHA animal house in accordance with Australian animal rights 
and regulation standards. The mice (18.06–22.28 g body weight) were confined in plastic cages with free 
access to pelleted food and water. They were kept under a specific pathogen-free environment at regu-
lated temperature (22 °C) and lighting (12 h cycle). Efforts were made to reduce the number of animals 
used in the TNBS experiment and also to minimise their suffering.
The samples (1 mg) were dissolved in 10 μ L of DMSO followed by addition of DPBS (1 mL) under ster-
ile conditions. Mice were randomly divided into four groups with five mice in each cage as: Naive, TNBS, 
Veratroyl (coded for 14-veratroylpseudaconine (2)) and Bhutamine (coded for 14-O-acetylneoline (3)). 
The active alkaloid 14-O-acetylneoline (3) was later subjected to dose-dependent activity analyses using 
mice in the following groups: Naive, TNBS, BHUT-10 (coded for 10 μ g dose)/TNBS, BHUT-20 (coded 
for 20 μ g dose)/TNBS and BHUT-50 (coded for 50 μ g dose)/TNBS. As coded above, the experimental 
mice received the test compound doses of 10, 20 and 50 μ g, respectively. These doses were prepared in 
DPBS to make a total injectable volume of 200 μ L/mouse. Mice were administered test compounds via 
the intra-peritoneal (i.p.) route and left in their cages for 5–6 hours prior to administration of TNBS.
Standard TNBS colitis protocols33–35,40,41 were employed. The TNBS (positive controls), BHUT-10, 
BHUT-20 and BHUT-50 groups were administered TNBS intra-rectally (3 mg per mice in 45% EtOH, 
100 μ L/mice) to induce transient colitis. Xylazine-ketamine solution was prepared as 5 mg/kg and 
50 mg/kg, respectively. Mice were anaesthetized using a 200 μ L of this solution and TNBS was care-
fully administered intra-rectally using a SRPLO I.V. catheter (Radiopaque/ETFE, Gauge 20G × 11/4”, 
I.D. 0.80 × 32 mm, Terumo Corporation) lubricated with K.Y jelly. To assure the distribution of TNBS 
within the entire colon lumen, mice were carefully maintained at a 90° angle (head down position) for 
2 mins and then returned to their cages.
Clinical and macroscopic assessment of mice with TNBS-induced colitis. Throughout the 
experiment, mice were monitored daily for weight loss and changes in clinical signs for 3 days. The 
clinical signs of disease including changes in body weight, mobility, piloerection and faecal consistency 
were scored from 0–2, zero being normal and 2 being diseased. A score of “0” was given when the mice 
gained weight, “1” when weight remained the same and “2” upon losing weight. For mobility, a score of 
“0” was given for normal, “1” for movement only after stimulation, and “2” for lethargic mice that exhib-
ited little to no movement after stimulation. Mice with no piloerection scored “0,” mild piloerection over 
the neck as “1” and severe piloerection all over the body as “2”. Normal faeces scored “0”, mild diarrhoea 
was scored “1” and severe diarrhoea with blood was scored “2”. On day 3 post-TNBS administration, the 
mice were euthanized and the colon harvested and then transferred to a petri dish with sterile DPBS. 
Tissues were opened longitudinally, washed with DPBS, placed under a microscope (Olympus SZ61, 
0.67-4.5x), assessed for changes in macroscopic appearance, and then scored for pathological changes as 
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follows: adhesion (0 to 3), bowel wall thickening (0 to 3), mucosal oedema (0 to 3), ulceration (0 to 3), 
and colon length as described previously47.
Histological analysis and evaluation of microscopic damage. Distal colon tissue (1 cm) obtained 
from representative groups of healthy mice (Naive) and mice that received TNBS and different doses of 
14-O-acetylneoline were placed into 4% paraformaldehyde (1 mL) and stored for 24 hr at 4 °C. These 
tissues were then transferred to EtOH (70%) prior to being embedded in paraffin. Sections were stained 
with haematoxylin and eosin (H/E), observed for histological changes by light microscopy and his-
tological photomicrographs (x 200) were captured. Histological and microscopic observation included 
changes in overall colon structure involving inflammation, gut lining, goblets cells, lamina propria, and 
colon wall.
Cell preparation and IFN-γ quantification. Colon pieces (1 cm) were collected after mice were 
euthanized and placed in sterile 24 well tissue culture plates with 500 μ L of complete medium with foetal 
bovine serum (5 ml), 100 U of penicillin/ml, 100 μ g of streptomycin, β -mercaptoethanol (55 μ M), HEPES 
buffer (10 mM). Tissues were cultured for 24 hr at 37 °C after which supernatants were collected and 
stored at − 80 °C until further use. Colon culture supernatants were thawed and IFN-γ levels quantified 
using a sandwich enzyme-linked immunosorbent assay (ELISA) (mouse IFN-γ ELISA Ready-SET-Go! 
eBiosciences) following the manufacturer’s instructions. OD490 were measured using a POLARstar 
Omega plate reader (BMG LABTECH).
Statistical analyses. All data was analysed with GraphPad Prism (version 6.0e). Statistical analy-
ses were performed using the 2-way ANOVA, multiple comparisons of treatment group over different 
time. Unpaired Mann-Whitney non-parametric tests were used for comparing pooled data from repeated 
experiments. All values are expressed as means ± SEM. The significance p-values were calculated using 
two-tailed tests with over 95% confidence levels. Results were considered significant when P < 0.05. 
Statistical analyses were performed by pooling data from groups of mice from two independent but 
reproducible experiments such that N = 8–10 mice per group.
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